New hope for hard-to-treat lung cancer: drug combo targets HER2 mutations
NCT ID NCT07377916
First seen Feb 01, 2026 · Last updated May 03, 2026 · Updated 11 times
Summary
This study tests a combination of two drugs (SHR-A1811 and pertuzumab) in 60 adults with advanced non-small cell lung cancer that has a specific change called HER2 alteration and has worsened after at least one prior treatment. The goal is to see if the combo can shrink tumors or slow the cancer's growth. Participants will receive the drugs until the cancer progresses or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.